PLEASANTON, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will be participating in the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13.
Gary F. Burbach, president and chief executive officer, will provide an update on the company, beginning at 11 a.m., Pacific Standard Time (2 p.m., Eastern Standard Time).
The presentation will be available through the conference web site at http://metameetings.com/webcasts/jpmorgan/healthcare10/directlink?ticker=THOR, or on the company's web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS (Left Ventricular Assist System) with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.
SOURCE Thoratec Corporation